Pacira BioSciences Achieves Milestone with New Patent
Pacira BioSciences, Inc., an industry leader in non-opioid pain therapies, has received a significant boost with the issuance of U.S. Patent No. 12,156,940. This milestone patent, known as the ‘940 patent, focuses on the manufacturing methods of Bupivacaine Multivesicular Liposomes, specifically for its flagship product, EXPAREL.
Reinforcing EXPAREL's Intellectual Property
The U.S. Patent and Trademark Office recently awarded this patent, which serves to solidify the chemical composition of EXPAREL, a groundbreaking injectable suspension designed to provide long-lasting pain relief following surgery. The patent exemplifies Pacira's commitment to innovation and is projected to extend the patent protection until July 2044.
Leadership Insights
Frank D. Lee, the chief executive officer of Pacira, expressed pride in the new patent, stating, “Our goal is to build a broad portfolio of intellectual property to safeguard our EXPAREL franchise well beyond 2044.” This sentiment reflects the company’s strong dedication to maintaining a competitive edge through continuous innovation and patent protection.
Strategic Actions Following Patent Approval
With the addition of the ‘940 patent, Pacira intends to take legal action against Jiangsu Hengrui Pharmaceuticals Co. LTD. for patent infringement. This lawsuit targets their U.S. distributor, Fresenius Kabi USA, LLC, asserting that these companies are infringing on Pacira's intellectual property rights.
Current Legal Landscape
Pacira is also engaged in an active lawsuit against eVenus Pharmaceutical Laboratories, Inc., addressing further patent infringements. These actions underline Pacira’s assertive stance in defending its innovations and trademarks, emphasizing the value it places on its research and development efforts.
Expanding the Patent Family
In addition to the ‘940 patent, the company recently received further patents, U.S. Patent Nos. 12,151,024 and 12,144,890. These patents are linked to the existing family of patents protecting EXPAREL and contribute to the broad spectrum of intellectual property safeguarding this critical product.
Future Developments in Pain Management
Pacira remains committed to advancing non-opioid treatments that improve patient outcomes. Their portfolio also includes ZILRETTA, an extended-release injectable for knee pain management, and ioveraº, a novel tool providing immediate, drug-free pain relief through controlled cold therapy. Each of these products reflects Pacira's innovative approach to pain management.
About Pacira BioSciences
Founded on the principle of delivering innovative, non-opioid therapies, Pacira BioSciences is reshaping the landscape of pain management. As they continue their mission to transform patient lives, they are also advancing PCRX-201, a groundbreaking gene therapy aimed at treating widespread ailments such as osteoarthritis. This effort positions Pacira as a frontrunner in the development of effective pain management solutions.
Frequently Asked Questions
What is the significance of the new patent awarded to Pacira?
The new patent protects the composition of EXPAREL until 2044, reinforcing Pacira's intellectual property and innovative processes.
How will the patent impact Pacira's market position?
This patent solidifies Pacira's competitive edge and enables it to defend against potential infringement more effectively.
What products does Pacira currently offer?
Pacira offers EXPAREL for post-surgical pain management, ZILRETTA for knee pain, and ioveraº for immediate cold therapy pain relief.
What legal actions is Pacira taking related to their patents?
Pacira plans to file a lawsuit against Jiangsu Hengrui Pharmaceuticals and has ongoing litigation against eVenus Pharmaceutical for patent infringement.
What future treatments is Pacira developing?
Pacira is advancing PCRX-201, a novel gene therapy aimed at treating conditions such as osteoarthritis, expanding their portfolio of pain management solutions.
